Chest
Volume 140, Issue 4, Supplement, 23–26 October 2011, Page 1045A
Journal home page for Chest

Slide Presentations: Wednesday, October 26, 2011 | October 2011
Imatinib Improves Exercise Capacity and Hemodynamics at 24 Weeks as Add-on Therapy in Symptomatic Pulmonary Arterial Hypertension Patients: The IMPRES Study

https://doi.org/10.1378/chest.1216523Get rights and content

Section snippets

Abstract

PURPOSE: Pulmonary arterial hypertension (PAH) involves enhanced pulmonary vascular remodeling and proliferation. Currently approved therapies for PAH target the prostacyclin, endothelin and nitric oxide pathways. Imatinib is a novel orally-active anti-proliferative therapy in clinical development for PAH. The IMPRES study evaluated its efficacy, safety and tolerability over 24 weeks in patients with persistent PAH despite optimized therapy with established PAH therapies.

METHODS: Double-blind,

References (0)

Cited by (0)

View full text